Viridian Therapeutics, Inc.(VRDN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VRDN Viridian Therapeutics, Inc.

盘后交易 10-01 16:41:54 EDT

18.99

-1.60

-7.77%

盘后19.26

+0.27+1.42%

16:31 EDT

最高20.61	最低18.99	成交量337.33万
今开20.61	昨收20.59	日振幅7.87%
总市值21.51亿	流通市值19.18亿	总股本1.13亿
成交额6,515万	换手率3.34%	流通股本1.01亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VRDN","market":"US","secType":"STK","nameCN":"Viridian Therapeutics, Inc.","latestPrice":18.99,"timestamp":1790884800000,"preClose":20.59,"halted":0,"volume":3373308,"hourTrading":{"tag":"盘后","latestPrice":19.26,"preClose":18.99,"latestTime":"16:31 EDT","volume":542961,"amount":10310996.079027,"timestamp":1790886667618,"change":0.27,"changeRate":0.014218,"amplitude":0.014218},"delay":0,"changeRate":-0.07770762506070915,"floatShares":101000000,"shares":113292269,"eps":-3.45791,"marketStatus":"盘后交易","change":-1.6,"latestTime":"10-01 16:41:54 EDT","open":20.61,"high":20.61,"low":18.99,"amount":65154044.09718,"amplitude":0.078679,"askPrice":21,"askSize":220,"bidPrice":19,"bidSize":73,"shortable":3,"etf":0,"ttmEps":-3.45791,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790899200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":20.59,"preHourTrading":{"tag":"盘前","latestPrice":20.53,"preClose":20.59,"latestTime":"09:29 EDT","volume":5109,"amount":105281.74031699999,"timestamp":1790861399985,"change":-0.06,"changeRate":-0.002914,"amplitude":0.135017},"postHourTrading":{"tag":"盘后","latestPrice":19.26,"preClose":18.99,"latestTime":"16:31 EDT","volume":542961,"amount":10310996.079027,"timestamp":1790886667618,"change":0.27,"changeRate":0.014218,"amplitude":0.014218},"volumeRatio":2.037114,"impliedVol":1.0837,"impliedVolPercentile":0.8167},"requestUrl":"/m/hq/s/VRDN","defaultTab":"news","newsList":[{"id":"1110186795","title":"Viridian Therapeutics 公布2026年第二季度财报，并强调近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1110186795","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110186795?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:02","pubTimestamp":1786014131,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics, Inc. 近日对外披露了其2026年第二季度的财务业绩，同时着重强调了公司在近期所取得的业务进展。这份报告不仅展示了公司当前的财务状况，还揭示了其核心项目的推进情况，为投资者提供了全面的视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157117238","title":"Viridian Therapeutics高管透露，典型75公斤患者五次Lumvoa输注的批发采购成本约为45万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157117238","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157117238?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:29","pubTimestamp":1782736176,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics公司高管指出，对于一名体重75公斤的典型患者而言，完成五次Lumvoa药物输注的批发采购成本大约在45万美元左右。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2468319806.SGD","BK4534","AMGN","LU0122379950.USD","LU0320765992.SGD","LU2089984988.USD","BK4581","BK4139","IE00BFTCPJ56.SGD","BK4566","VRDN","BK4599","LU2242646821.SGD","LU2112291526.USD","LU0058720904.USD","BK4585","LU1057294990.SGD","LU1061106388.HKD","LU0889565916.HKD","LU0868494617.USD","IE00B4R5TH58.HKD","LU2242652126.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU0109394709.USD","IE00B2B36J28.USD","BK4533","IE0002141913.USD","LU0289739699.SGD","SG9999001440.SGD","LU1023059063.AUD","LU1571399168.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103973070","title":"Viridian高管表示：其甲状腺眼病药物Lumvoa五次输注定价与安进Tepezza八次输注大致持平 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1103973070","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103973070?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:27","pubTimestamp":1782736031,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics公司高管在电话会议中透露，其用于治疗甲状腺眼病的药物Lumvoa，五次输注疗程的定价方案，与竞争对手安进公司旗下药物Tepezza的八次标准输注疗程总价大致相当。这一价格策略旨在为市场提供更具成本效益的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU2242646821.SGD","IE00BFTCPJ56.SGD","BK4599","LU2242652126.USD","LU2468319806.SGD","SG9999001440.SGD","LU2112291526.USD","LU1023059063.AUD","BK4585","LU1983299246.USD","BK4139","AMGN","LU0889565916.HKD","LU1571399168.USD","IE00BJT1NW94.SGD","LU1057294990.SGD","VRDN","IE0009355771.USD","IE00B2B36J28.USD","IE0002141913.USD","IE00B4R5TH58.HKD","BK4581","LU1061106388.HKD","LU0122379950.USD","LU0320765992.SGD","BK4533","BK4534","BK4588","LU0289739699.SGD","LU2089984988.USD","IE00BJJMRZ35.SGD","LU0868494617.USD","LU0058720904.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142738747","title":"Viridian Therapeutics盘前大涨10.8%，其甲状腺眼疾药物获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1142738747","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142738747?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:13","pubTimestamp":1782720798,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics的股价在盘前交易时段飙升10.8%，此前该公司用于治疗甲状腺眼病的药物获得了美国食品药品监督管理局的批准。这一监管绿灯为该公司核心产品线的商业化铺平了道路，标志着其在应对这一自身免疫性疾病方面取得了关键进展。市场对此消息反应积极，投资者情绪显著提振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175250676","title":"Viridian Therapeutics宣布Lumvoa™ (veligrotug-vvze)获美国FDA批准上市，用于治疗甲状腺眼病","url":"https://stock-news.laohu8.com/highlight/detail?id=1175250676","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175250676?lang=zh_cn&edition=full","pubTime":"2026-06-27 06:00","pubTimestamp":1782511218,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics宣布，其创新药物Lumvoa已获得美国食品药品监督管理局的批准，并正式上市，用于甲状腺眼病的治疗。这一批准标志着Viridian Therapeutics在眼科治疗领域取得了一项重要进展。Lumvoa是一种针对特定靶点的生物制剂，其获批为甲状腺眼病患者提供了一种新的治疗选择。公司表示，将立即启动Lumvoa在美国的商业化进程，确保该药物能够尽快惠及有需要的患者。此次获批是基于多项临床研究的数据，这些数据证明了该疗法在改善疾病体征和症状方面的有效性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126546822","title":"Viridian Therapeutics与药明生物就Veligrotug达成生产供应协议 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1126546822","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126546822?lang=zh_cn&edition=full","pubTime":"2026-05-27 04:09","pubTimestamp":1779826159,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件披露，Viridian Therapeutics, Inc. 已与药明生物达成协议，后者将为其生产并供应在研药物Veligrotug。此项合作标志着Viridian在推进其核心管线产品Veligrotug的开发和未来商业化进程中，迈出了关键一步。通过携手全球领先的合同研究、开发与生产组织药明生物，Viridian旨在确保其候选药物能够获得高质量、可扩展的生产能力支持。Veligrotug是Viridian公司管线中一款备受关注的候选疗法。该份SEC文件的披露，向市场传达了Viridian在推进业务运营方面的具体进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173468024","title":"Viridian Therapeutics宣布上调2032年到期1.75%可转换优先票据与普通股同步公开发行规模，募资总额达3.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173468024","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173468024?lang=zh_cn&edition=full","pubTime":"2026-05-07 11:14","pubTimestamp":1778123684,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics, Inc. (简称：Viridian Therapeutics) 正式公布其同步公开发行方案的最新定价细节。此次发行包含2032年到期的1.75%可转换优先票据及公司普通股，且发行规模较原计划有所扩大。经调整后，两项发行的募资总额合计达到3.5亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192159112","title":"Viridian Therapeutics公布Reveal-2试验达主要终点，治疗效果具高度统计学意义","url":"https://stock-news.laohu8.com/highlight/detail?id=1192159112","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192159112?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:01","pubTimestamp":1777978874,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics公司宣布，其Reveal-2临床试验成功达到主要终点。数据显示，该试验治疗方案展现出显著的治疗效果，且结果具有高度统计学意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193766500","title":"Viridian Therapeutics高管表示，晚期试验数据公布后，公司对Elegrobart定价拥有充分灵活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1193766500","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193766500?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:43","pubTimestamp":1774874588,"startTime":"0","endTime":"0","summary":"在最新的电话会议中，Viridian Therapeutics公司的高层管理人员强调，随着其核心候选药物Elegrobart的晚期临床试验数据公布，公司在定价策略上拥有多种选择空间。\n这一表态表明，Viridian Therapeutics正积极评估市场反应与临床成果，以制定最优的商业化路径。公司对Elegrobart的定价灵活性，被视为其在竞争激烈的治疗领域中的一项关键优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109095775","title":"Viridian Therapeutics高管称公司资金充足，足以支撑运营至盈利阶段——电话会议实录","url":"https://stock-news.laohu8.com/highlight/detail?id=1109095775","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109095775?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:38","pubTimestamp":1774874300,"startTime":"0","endTime":"0","summary":"在最新电话会议中，Viridian Therapeutics公司高管明确表示，当前公司财务状况稳健，已获得足够资金支持各项业务持续开展，直至实现盈利目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166352219","title":"Viridian Therapeutics公布甲状腺眼疾药物后期试验数据 股价盘前重挫33.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166352219","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166352219?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:11","pubTimestamp":1774869101,"startTime":"0","endTime":"0","summary":"生物科技公司Viridian Therapeutics, Inc. (VRDN) 股价在盘前交易时段暴跌33.5%，此前该公司公布了其甲状腺眼病治疗药物的后期临床试验数据。\n这一急剧下跌反映了市场对该试验结果可能未达预期的担忧。甲状腺眼病是一种导致眼部组织发炎和突出的自身免疫性疾病，该治疗领域存在显著的未满足医疗需求。\n投资者正密切关注这些数据，以评估该药物未来的商业化前景及其为Viridian Therapeutics带来的潜在收入。此次股价波动凸显了生物科技股对临床试验结果的高度敏感性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162501022","title":"Viridian Therapeutics公布Elegrobart治疗活动性甲状腺眼病三期Reveal-1临床试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1162501022","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162501022?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:04","pubTimestamp":1774868683,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics, Inc.近日宣布，其针对活动性甲状腺眼病研发的药物Elegrobart，在三期临床试验Reveal-1中取得了积极的顶线结果。这项关键研究达到了其主要终点，显示出Elegrobart在改善患者眼球突出症状方面具有显著疗效。安全性方面，Elegrobart表现出良好的耐受性，其安全性与既往研究一致，未发现新的安全性信号。这些积极结果标志着Elegrobart在活动性甲状腺眼病治疗领域向前迈出了重要一步，为后续向监管机构提交申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163105553","title":"Viridian Therapeutics公司Reveal-1试验达到主要终点，Q4w眼球突出应答率具统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1163105553","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163105553?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:03","pubTimestamp":1774868622,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics公司宣布，其关键性临床试验Reveal-1成功达到主要研究终点。数据显示，每四周给药一次的方案在改善甲状腺眼病患者眼球突出方面，展现出具有统计学显著意义的应答率。这一积极结果标志着该公司在甲状腺眼病治疗领域的研发取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109883220","title":"异动解读 | 生物制药公司Viridian Therapeutics盘中大涨5.01% 潜在疗效获看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1109883220","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109883220?lang=zh_cn&edition=full","pubTime":"2025-03-07 04:26","pubTimestamp":1741292806,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Inc.(VRDN)今日盘中股价大涨5.01%,引发市场关注。该公司是一家临床阶段的生物制药公司,主攻肿瘤和罕见疾病的治疗药物开发。\n据了解,Viridian的候选产品VRDN-001是一种抗IGF-1R单克隆抗体,目前正在开发用于治疗甲状腺眼病患者。市场分析人士认为,如果该产品临床试验取得成功,将会大幅改善甲状腺眼病患者的生活质量,因此备受市场关注和期待。\n不过,目前VRDN-001仍处于临床试验阶段,未来能否最终获批上市还有待进一步数据验证。但该产品的潜在疗效已获资本市场初步认可,或是推动Viridian今日股价大涨的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 生物制药公司Viridian Therapeutics盘中大涨5.01% 潜在疗效获看好","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510335800","title":"Viridian Therapeutics, Inc.盘中异动 早盘股价大跌5.06%报17.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510335800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510335800?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:21","pubTimestamp":1739287319,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时21分，Viridian Therapeutics, Inc.股票出现波动，股价急速下挫5.06%。Viridian Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.62%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2577.70%、890.43%、345.86%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为52.11%、47.30%、37.99%。Viridian Therapeutics, Inc.公司简介：Viridian Therapeutics Inc 是一家临床阶段的生物制药公司，致力于开发多种候选产品，治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211232159a242067a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211232159a242067a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRDN","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509205872","title":"Viridian Therapeutics, Inc.盘中异动 早盘急速下跌5.04%报18.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509205872","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509205872?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:45","pubTimestamp":1738856717,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日23时45分，Viridian Therapeutics, Inc.股票出现异动，股价大幅跳水5.04%。Viridian Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为5552.09%、1348.99%、134.42%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Azitra Inc、Transcode Therapeutics, Inc.，振幅分别为103.10%、42.43%、39.93%。Viridian Therapeutics, Inc.公司简介：Viridian Therapeutics Inc 是一家临床阶段的生物制药公司，致力于开发多种候选产品，治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206234517abc4e50f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206234517abc4e50f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRDN","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507326670","title":"Viridian Therapeutics, Inc.盘中异动 下午盘快速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507326670","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507326670?lang=zh_cn&edition=full","pubTime":"2025-01-31 04:07","pubTimestamp":1738267662,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日04时07分，Viridian Therapeutics, Inc.股票出现波动，股价急速上涨5.04%。Viridian Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Dominari Holdings Inc.涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1811.25%、328.69%、253.86%，振幅较大的相关个股有Dominari Holdings Inc.、Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为70.55%、65.98%、64.10%。Viridian Therapeutics, Inc.公司简介：Viridian Therapeutics Inc 是一家临床阶段的生物制药公司，致力于开发多种候选产品，治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131040743a2348d3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131040743a2348d3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","VRDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505272140","title":"Viridian Therapeutics, Inc.盘中异动 早盘快速上涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505272140","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505272140?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:52","pubTimestamp":1737471141,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时52分，Viridian Therapeutics, Inc.股票出现波动，股价快速拉升5.05%。Viridian Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.13%。其相关个股中，Channel Therapeutics Corporation、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Dogwood Therapeutics, Inc.涨幅较大，Dogwood Therapeutics, Inc.、Dermata Therapeutics, Inc.、Channel Therapeutics Corporation较为活跃，换手率分别为633.15%、167.99%、126.52%，振幅较大的相关个股有Channel Therapeutics Corporation、Dogwood Therapeutics, Inc.、Atara Biotherapeutics, Inc.，振幅分别为92.63%、38.48%、17.50%。Viridian Therapeutics, Inc.公司简介：Viridian Therapeutics Inc 是一家临床阶段的生物制药公司，致力于开发多种候选产品，治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121225221960bbdc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121225221960bbdc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VRDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504160739","title":"Viridian Therapeutics, Inc.盘中异动 早盘股价大涨5.04%报17.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504160739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504160739?lang=zh_cn&edition=full","pubTime":"2025-01-17 23:13","pubTimestamp":1737126785,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日23时13分，Viridian Therapeutics, Inc.股票出现异动，股价快速拉升5.04%。Viridian Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。其相关个股中，Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Aditxt, Inc.、Silexion Therapeutics Corp、Aeon Biopharma, Inc.较为活跃，换手率分别为148.90%、22.45%、21.81%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为51.37%、47.91%、43.71%。Viridian Therapeutics, Inc.公司简介：Viridian Therapeutics Inc 是一家临床阶段的生物制药公司，致力于开发多种候选产品，治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117231305a225c4ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117231305a225c4ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRDN","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503642073","title":"Viridian Therapeutics, Inc.盘中异动 急速拉升5.46%报17.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503642073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503642073?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:31","pubTimestamp":1736951470,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时31分，Viridian Therapeutics, Inc.股票出现异动，股价快速上涨5.46%。Viridian Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Os Therapies Incorporated、Generation Bio Co.、Exicure, Inc.涨幅较大，Windtree Therapeutics, Inc.、Os Therapies Incorporated、Phio Pharmaceuticals Corp.较为活跃，换手率分别为184.25%、56.33%、51.74%，振幅较大的相关个股有Os Therapies Incorporated、Klotho Neurosciences, Inc.、Vincerx Pharma, Inc.，振幅分别为18.99%、12.00%、10.72%。Viridian Therapeutics, Inc.公司简介：Viridian Therapeutics Inc 是一家临床阶段的生物制药公司，致力于开发多种候选产品，治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152231109604b39f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152231109604b39f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRDN","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viridiantherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0392},{"period":"1month","weight":-0.111},{"period":"3month","weight":0.0613},{"period":"6month","weight":0.0929},{"period":"1year","weight":-0.0459},{"period":"ytd","weight":-0.3384}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viridian Therapeutics, Inc.于2014年6月17日在特拉华州成立，该公司是一家生物制药公司，专注于研究和开发针对严重和罕见疾病的潜在最佳药物。该公司瞄准的是竞争不激烈的疾病领域，在这些领域，已上市的疗法往往为提高疗效、安全性或给药便利性留出空间。该公司认为，第一代药物很少代表最佳解决方案，特别是在罕见病领域，而且有潜力开发差异化、同类最佳的药物，从而改善患者的治疗效果、减少副作用、提高生活质量、扩大市场准入和加强市场竞争。该公司正在开发三种候选产品：VRDN-001、VRDN-002和VRDN-003，这些产品正在开发中，用于静脉注射或皮下注射，以治疗患有甲状腺眼病（TED）的患者。该公司最先进的项目VRDN-001是一种靶向IGF-1R的差异化人源化单克隆抗体，用于治疗TED。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.269131},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.083186},{"month":3,"riseRate":0.25,"avgChangeRate":-0.101161},{"month":4,"riseRate":0.583333,"avgChangeRate":0.000279},{"month":5,"riseRate":0.333333,"avgChangeRate":0.008151},{"month":6,"riseRate":0.583333,"avgChangeRate":0.009034},{"month":7,"riseRate":0.538462,"avgChangeRate":0.011548},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.059066},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.020088},{"month":10,"riseRate":0.25,"avgChangeRate":-0.0411},{"month":11,"riseRate":0.583333,"avgChangeRate":0.157254},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.069844}],"exchange":"NASDAQ","name":"Viridian Therapeutics, Inc.","nameEN":"Viridian Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viridian Therapeutics, Inc.(VRDN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viridian Therapeutics, Inc.(VRDN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viridian Therapeutics, Inc.,VRDN,Viridian Therapeutics, Inc.股票,Viridian Therapeutics, Inc.股票老虎,Viridian Therapeutics, Inc.股票老虎国际,Viridian Therapeutics, Inc.行情,Viridian Therapeutics, Inc.股票行情,Viridian Therapeutics, Inc.股价,Viridian Therapeutics, Inc.股市,Viridian Therapeutics, Inc.股票价格,Viridian Therapeutics, Inc.股票交易,Viridian Therapeutics, Inc.股票购买,Viridian Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viridian Therapeutics, Inc.(VRDN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viridian Therapeutics, Inc.(VRDN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}